These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 17690610)

  • 1. Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia.
    Anari S; Carding PN; Hawthorne MR; Deakin J; Drinnan MJ
    Laryngoscope; 2007 Oct; 117(10):1888-92. PubMed ID: 17690610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.
    Rubin AD; Wodchis WP; Spak C; Kileny PR; Hogikyan ND
    Arch Otolaryngol Head Neck Surg; 2004 Apr; 130(4):415-20. PubMed ID: 15096423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voice handicap index results for older patients with adductor spasmodic dysphonia.
    Wingate JM; Ruddy BH; Lundy DS; Lehman J; Casiano R; Collins SP; Woodson GE; Sapienza C
    J Voice; 2005 Mar; 19(1):124-31. PubMed ID: 15766857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of essential voice tremor: a study of 34 cases.
    Sulica L; Louis ED
    Laryngoscope; 2010 Mar; 120(3):516-28. PubMed ID: 20066728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results.
    Paniello RC; Barlow J; Serna JS
    Laryngoscope; 2008 Mar; 118(3):564-8. PubMed ID: 18216744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voice-related Quality of Life in laryngectomees: assessment using the VHI and V-RQOL symptom scales.
    Kazi R; De Cordova J; Singh A; Venkitaraman R; Nutting CM; Clarke P; Rhys-Evans P; Harrington KJ
    J Voice; 2007 Nov; 21(6):728-34. PubMed ID: 16815670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia.
    Liu TC; Irish JC; Adams SG; Durkin LC; Hunt EJ
    J Otolaryngol; 1996 Apr; 25(2):66-74. PubMed ID: 8683655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.
    Casserly P; Timon C
    J Laryngol Otol; 2008 Jan; 122(1):52-6. PubMed ID: 17470307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.
    Sahai A; Dowson C; Khan MS; Dasgupta P
    BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptual analyses of spasmodic dysphonia before and after treatment.
    Cannito MP; Woodson GE; Murry T; Bender B
    Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1393-9. PubMed ID: 15611398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia.
    Klein AM; Stong BC; Wise J; DelGaudio JM; Hapner ER; Johns MM
    Otolaryngol Head Neck Surg; 2008 Sep; 139(3):421-3. PubMed ID: 18722224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Do psychological factors change in patients with spasmodic dysphonia after injections with botulinum-toxin?].
    Kiese-Himmel C; Reeh M; Liebeck H; Zwirner P
    Laryngorhinootologie; 2002 Oct; 81(10):683-9. PubMed ID: 12397516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia.
    Damrose JF; Goldman SN; Groessl EJ; Orloff LA
    J Voice; 2004 Sep; 18(3):415-22. PubMed ID: 15331116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
    Adams SG; Hunt EJ; Charles DA; Lang AE
    J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined modality treatment of adductor spasmodic dysphonia.
    Silverman EP; Garvan C; Shrivastav R; Sapienza CM
    J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia.
    Chang CY; Chabot P; Thomas JP
    Otolaryngol Head Neck Surg; 2007 Jun; 136(6):894-9. PubMed ID: 17547976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and demographics in patients with spasmodic dysphonia.
    Schweinfurth JM; Billante M; Courey MS
    Laryngoscope; 2002 Feb; 112(2):220-3. PubMed ID: 11889373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.